Ionis Pharmaceuticals IONS Ionis Operations — Drug Development Expenses

Similar metrics at other companies

AVBDevelopment / Redevelopment — Operating Expenses

$10.04M+102%

AVBPDrug Firmonertinib — Research And Development Expense

$15.08M+5.4%

AGPUDrug Discovery Services — Research And Development Expense

$2.14M+283%

FRPHDevelopment — Operating Expenses

$52K-93.6%

WHW

WHWKAntibody Drug Conjugate — Research And Development Expense Contract And Manufacturing Expense

$6.68M—

ZYMEOther drug supply — Research and development collaborations

$1.66M+23,671%

FAQ

What is Ionis Pharmaceuticals's ionis operations — drug development expenses?

Ionis Pharmaceuticals (IONS) reported ionis operations — drug development expenses of $103.96M in Q2 2026.

How has Ionis Pharmaceuticals's ionis operations — drug development expenses changed year-over-year?

Ionis Pharmaceuticals's ionis operations — drug development expenses decreased by 11.7% year-over-year, from $117.69M to $103.96M.

What is the long-term trend for Ionis Pharmaceuticals's ionis operations — drug development expenses?

Over 3 years (2022 to 2025), Ionis Pharmaceuticals's ionis operations — drug development expenses has grown at a 4.5% compound annual growth rate (CAGR), from $426.23M to $486.2M.

What does ionis operations — drug development expenses mean?

These expenses cover the costs of conducting clinical trials, regulatory filings, and the advancement of drug candidates through the development lifecycle. It is a critical measure of the capital required to move assets toward commercial readiness.